For the year ending 2025-12-31, CELUW had $5,395K increase in cash & cash equivalents over the period. -$13,254K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Capital expenditures | 0 |
| Rebound asset acquisition | 0 |
| Proceeds from sanuwave convertible note receivable | 0 |
| Net cash provided by investing activities | 0 |
| Proceeds from warrants and short-term debt - related parties | 0 |
| Proceeds from issuance of short-term debt - unaffiliated | 0 |
| Repayment of short-term debt - unaffiliated | 0 |
| Payment of sepa commitment fee | 0 |
| Transaction costs related to the issuance of promissory notes with warrants | 40 |
| Proceeds from issuance of promissory notes with warrants | 10,000 |
| Proceeds from the sale of common stock in june 2025 pipe | 1,035 |
| Proceeds from the sale of common stock and warrants in july 2025 pipe | 2,000 |
| Proceeds from related party note with ktl warrant | 6,812 |
| Proceeds from the exercise of stock options | 108 |
| Cash proceeds from merchant cash advance | 3,286 |
| Repayment of merchant cash advance | 2,588 |
| Proceeds from the exercise of warrants by dragasac | 2,460 |
| Repayment of short-term debt - related party | 121 |
| Proceeds from issuance of preferred stock with warrants in pipe offering | 2,000 |
| Transaction costs from issuing of preferred stock with warrants in pipe offering | 210 |
| Tax withholding on vesting of restricted stock units | 193 |
| Repayment of related party notes | 5,900 |
| Net cash provided by financing activities | 18,649 |
| Issuance of common stock to palantir as consideration for settlement agreement | 0 |
| Issuance of common stock to yorkville for debt extension and sepa commitment fee | 0 |
| Change in fair value of contingent stock consideration | 0 |
| Other, net | 0 |
| Accrued r&d software | 0 |
| Depreciation and amortization | 7,295 |
| Non cash lease expense | 110 |
| Gain on amortization of licensing obligation | 1,911 |
| Provision for credit losses | 1,353 |
| Change in fair value of warrant liabilities | 3,318 |
| Change in fair value of derivative liability | 65 |
| Inventory reserve for obsolescence | 102 |
| Impairment of preferred stock investment | 2,890 |
| Loss on issuance of common stock to yorkville in connection with the side letter | 382 |
| Loss on issuance of common stock in connection with the settlement of debt | 73 |
| Issuance of warrants for strategic advisory agreement | 1,259 |
| Issuance of common stock due to strategic advisory agreement | 108 |
| Loss on issuance of convertible note with warrants | -2,335 |
| Issuance of warrants to preferred stockholders in consideration of forbearance agreement | 49 |
| Gain on forgiveness of interest | 991 |
| Share-based compensation expense | 10,378 |
| Director fees paid with rsus | 264 |
| Issuance of common stock for consulting expense | 705 |
| Loss on extinguishment of debt | -6,356 |
| Change in fair value of debt | 1,809 |
| Non cash interest expense | 4,915 |
| Accounts receivable | -7,551 |
| Inventory | -10,246 |
| Prepaid expenses and other assets | 40 |
| Accounts payable | 3,126 |
| Accrued expenses and other liabilities | 13,452 |
| Lease liabilities | 350 |
| Deferred income tax liabilities | 3 |
| Deferred revenue | -1,091 |
| Net loss | -91,716 |
| Inventory impairment | 4,335 |
| Net cash used in operating activities | -13,254 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 5,395 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 5,395 |
| Cash, cash equivalents and restricted cash at beginning of year | 10,977 |
| Cash, cash equivalents and restricted cash at end of year | 16,372 |
Celularity Inc (CELUW)
Celularity Inc (CELUW)